Clopidogrel Versus Ticagrelor in Type-2 Diabetes

CLOpidogrel Versus TIcagreLor for Antiplatelet Maintenance in DIAbetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study

CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with percutaneous coronary intervention (PCI).

Inclusion Criteria:

• type 2 diabetes mellitus
• stable coronary disease
• coronary revascularization with PCI at least 1 month prior to recruitment

Exclusion Criteria:

• acute coronary syndrome
• platelet count <70x109/l
• active bleeding or bleeding diathesis
• history of intracranial bleeding
• gastrointestinal bleeding <6 months
• cerebrovascular accident <3 months
• history of malignancy
• concomitant need for oral anticoagulant therapy
• severe liver disease or chronic renal failure (glomerular filtration rate <30 ml/min /1.73m2)